- Email: [email protected]
Abstract: P490 EFFICACY, SAFETY AND TOLERABILITY OF A FIXED DOSE COMBINATION OF TELMISARTAN + ATORVASTATIN IN ADULT INDIAN PATIENTS WITH HYPERTENSION AND DYSLIPIDEMIA
Poster - PHARMACOLOGY OF CVD - Polypharmacy Abstract: P490 Citation: Atherosclerosis Supplement 2009, Vol. 10, Issue 2
EFFICACY, SAFETY AND TOLERABILITY OF A FIXED DOSE COMBINATION OF TELMISARTAN + ATORVASTATIN IN ADULT INDIAN PATIENTS WITH HYPERTENSION AND DYSLIPIDEMIA A Sharma1, S Vithiavathi3, M Mylaswamy3, T Shrikanth4, K Satish Ramana5, C Bolmall1, V Baliga1 1
Medical Services, Glenmark Pharmaceuticals Ltd, Mumbai; 2Medicine, Aarupadai Veedu Medical College & Hospital, Puducherry; 3Medicine, Sumith Hospital, Coimbatore; 4Medicine, New Hope Medical Centre, Chennai; 5Medicine, Sri Raghavendra Hospital, Bengaluru Objectives: A fixed-dose combination of an anti-hypertensive + statin appears to a useful option in hypertensive dyslipidemic patients . This assesor-blind study was conducted to evaluate efficacy and safety of a fixed-dose combination of Telmisartan40mg+Atorvastatin10mg in adult Indian patients with hypertensive dyslipidemia Methods: Patients(n=212)with established Hypertensive dyslipidemia were treated with the combination for 8 weeks after obtaining their informed consent and approval from ethics committee. Efficacy parameters included improvements in blood pressure levels and lipid profile.Safety parameters included monitoring adverse events. Results: A total 207 patients completed the study(5 dropouts). A significant reduction(p<0.05) in both systolic(22.2%)and diastolic(12.9%)blood pressure and the lipid parameters like total cholesterol(34.7%), LDL-cholesterol(28.1%), Triglycerides(28.1%) and increase in HDL Cholesterol levels(19.3%) was noted after therapy. Sixteen patients reported mild to moderate adverse event like gastritis, headache, nausea , myalgia, flatulence and diarrhoea. Conclusion:The fixed-dose combination of Telmisaratan 40 mg+atorvastatin 10mg is effective in improving both blood pressure and lipid parameters and hence could be a useful therapeutic option in hypertensive patients with dyslipidemia. Funding: The study was sponsored by Glenmark Pharmaceuticals Ltd., India.
EFFICACY, SAFETY AND TOLERABILITY OF A FIXED DOSE COMBINATION OF TELMISARTAN + ATORVASTATIN IN ADULT INDIAN PATIENTS WITH HYPERTENSION AND DYSLIPIDEMIA A Sharma1, S Vithiavathi3, M Mylaswamy3, T Shrikanth4, K Satish Ramana5, C Bolmall1, V Baliga1 1
Medical Services, Glenmark Pharmaceuticals Ltd, Mumbai; 2Medicine, Aarupadai Veedu Medical College & Hospital, Puducherry; 3Medicine, Sumith Hospital, Coimbatore; 4Medicine, New Hope Medical Centre, Chennai; 5Medicine, Sri Raghavendra Hospital, Bengaluru Objectives: A fixed-dose combination of an anti-hypertensive + statin appears to a useful option in hypertensive dyslipidemic patients . This assesor-blind study was conducted to evaluate efficacy and safety of a fixed-dose combination of Telmisartan40mg+Atorvastatin10mg in adult Indian patients with hypertensive dyslipidemia Methods: Patients(n=212)with established Hypertensive dyslipidemia were treated with the combination for 8 weeks after obtaining their informed consent and approval from ethics committee. Efficacy parameters included improvements in blood pressure levels and lipid profile.Safety parameters included monitoring adverse events. Results: A total 207 patients completed the study(5 dropouts). A significant reduction(p<0.05) in both systolic(22.2%)and diastolic(12.9%)blood pressure and the lipid parameters like total cholesterol(34.7%), LDL-cholesterol(28.1%), Triglycerides(28.1%) and increase in HDL Cholesterol levels(19.3%) was noted after therapy. Sixteen patients reported mild to moderate adverse event like gastritis, headache, nausea , myalgia, flatulence and diarrhoea. Conclusion:The fixed-dose combination of Telmisaratan 40 mg+atorvastatin 10mg is effective in improving both blood pressure and lipid parameters and hence could be a useful therapeutic option in hypertensive patients with dyslipidemia. Funding: The study was sponsored by Glenmark Pharmaceuticals Ltd., India.